76.6% of patients were alive one year after starting treatment
Dr Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center in New York, presented results from a trial of the drug daraxonrasib at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona. In the trial, the tumours of 90% of the 61 patients stopped growing, just over 60% of patients had their tumours shrink or disappear, and about 8% of patients had no detectable cancer on CT scans. The Guardian reported that the pill can shrink and potentially eliminate pancreatic tumours.
The participants had recently been diagnosed with advanced pancreatic cancer that had spread to other parts of the body. The cancer became undetectable in one in 12 of the patients given daraxonrasib, and tumours stopped growing in almost all of the 61 patients.
A year after starting treatment, 76.6% of patients were alive, a rate that compares with the 40% to 45% of patients given chemotherapy alone who survive a year. Patients were followed for an average of a year and a half, and some did not see the cancer return during that period.
Park said the findings were “this is the closest to cure”, adding that he had never seen so many tumours disappear in patients whose cancer had spread.
“We are beginning to see not only a higher percentage of tumour response rates, but also deeper responses and a near doubling in the duration of disease control, which may eventually translate into longer survival,” he said.
“The median follow-up is 18 months. Just imagine, in an average of 18 months your disease just disappears on the CT scan … that’s closest to complete remission … it’s incredible.”
Doctors said the pill cannot yet be considered a cure and that they do not know how long it can keep the disease at bay. They said the results are encouraging because the treatment appears to offer patients more time, even if it does not cause full remission.
Half of all people diagnosed with pancreatic cancer die within three months, and only about 3% of patients survive for five years when the disease spreads to other organs. Pancreatic cancer has the lowest survival rate of all common cancers in the UK.
Daraxonrasib is a KRAS inhibitor treatment, which works by locking on to and shutting off certain mutations found in most pancreatic cancers. Those mutations drive tumour growth. There are hopes the treatment could work for dozens of other cancers because they can have similar mutations.
Michelle Mitchell, Cancer Research UK’s chief executive, said more research was needed, while adding: “This is the biggest leap forward we’ve seen in decades for pancreatic cancer patients and could offer real hope to people facing one of the deadliest and most difficult-to-treat cancers.”
“These results raise the exciting possibility that this breakthrough could eventually pave the way for treating other cancers that carry Kras gene mutations. More trials are now needed before this treatment can be assessed for use on the NHS and despite this advance, pancreatic cancer survival is still very low.”
Longer studies will be conducted to see whether any of the cancers can be put into remission, leaving open how long the responses last. Until that evidence emerges, the trial recorded that just over 60% of patients had their tumours shrink or disappear and about 8% had no detectable cancer on CT scans. The trial reported that 76.6% of patients were alive one year after treatment, compared with the 40% to 45% of patients given chemotherapy alone who usually survive a year. The drug is not a demonstrated cure.